Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Antibody-cytokine fusion proteins combine the unique targeting ability of antibodies with the multifunctional activity of cytokines. Here, we demonstrate the therapeutic efficacy of such constructs for the treatment of hepatic and pulmonary metastases of different melanoma cell lines. Two antibody-interleukin 2 (IL-2) fusion proteins, ch225-IL2 and ch14.18-IL2, constructed by fusion of a synthetic sequence coding for human IL-2 to the carboxyl end of the Cgamma1 gene of the corresponding antibodies, were tested for their therapeutic efficacy against xenografted human melanoma in vivo. Tumor-specific fusion proteins completely inhibited the growth of hepatic and pulmonary metastases in C.B-17 scid/scid mice previously reconstituted with human lymphokine-activated killer cells, whereas treatment with combinations of the corresponding antibodies plus recombinant IL-2 only reduced the tumor load. Even when treatment with fusion proteins was delayed up to 8 days after inoculation of tumor cells, it still resulted in complete eradication of micrometastases that were established at that time point. Selection of tumor cell lines expressing or lacking the targeted antigen of the administered fusion protein proved the specificity of the observed antitumor effect. Biodistribution analysis demonstrated that the tumor-specific fusion protein accumulated not only in subcutaneous tumors but also in lungs and livers affected with micrometastases. Survival times of animals treated with the fusion protein were more than doubled as compared to those treated with the combination of the corresponding antibody plus IL-2. Our data demonstrate that an immunotherapeutic approach using cytokines targeted by antibodies to tumor sites has potent effects against disseminated human melanoma.
Becker
J C
JC
Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Pancook
J D
JD
Gillies
S D
SD
Mendelsohn
J
J
Reisfeld
R A
RA
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001483:Base Sequence; D002460:Cell Line; D017931:DNA Primers; D066246:ErbB Receptors / Q000276:immunology*; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000096:biosynthesis / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D008545:Melanoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors; D014183:Transplantation, Heterologous
D000906:Antibodies; D017931:DNA Primers; D005732:Gangliosides; D000922:Immunotoxins; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C019403:ganglioside, GD2; D066246:ErbB Receptors